|1. TYPE OF DRUG – Clindamycin|
|Clindamycin is an antibiotic that fights bacteria in the body.
|2. INDICATIONS (USE) – Clindamycin|
|Clindamycin is an antibiotic useful for the treatment of a number of bacterial infections. This includes middle ear infections, bone or joint infections, pelvic inflammatory disease, strep throat, pneumonia, and endocarditis among others. Cracks in the skin
loss of heat from the body
red, swollen skin
scaly skin It can be useful against some cases of methicillin-resistant Staphylococcus aureus (MRSA). It may also be used for acne and in addition to quinine for malaria. It is available by mouth, intravenously, and as a cream to be applied to the skin or in the vagina
|3. MECHANISM OF ACTION (MOA) – Clindamycin|
|Clindamycin has a primarily bacteriostatic effect. It is a bacterial protein synthesis inhibitor by inhibiting ribosomal translocat9oion, in a similar way to macrolides. It does so by binding to the 50S rRNA of the large bacterial ribosome subunit.
The structures of the complexes between several antibiotics (including clindamycin) and a Deinococcus radiodurans ribosome have been solved by X-ray crystallography by a team from the Max Planck Working Groups for Structural Molecular Biology, and published in the journal Nature
|4. ROUTES OF ADMINISTRATION – Clindamycin|
|5. ONSET OF EFFECT OR ACTION – Clindamycin|
|Within 30 mins.
|6. DOSAGE (DOSING INFORMATION) – Clindamycin|
|Adults: mild to mod inf :150-300 mg QID severe info: 300-450 mgQID. ALT-Rx forPL.falciparum:20 g/kg/day -5days.
Children: >1 month age –inj 20-40 mg/kg/day in 3-4 div doses.< 1 month :15-20 mg/kg/day in div doses.
|7. HALF LIFE (DURATION OF ACTION) – Clindamycin|
|8. ADVERSE EFFECTS OR SIDE EFFECTS – Clindamycin|
|9. CONTRAINDICATIONS – Clindamycin|
|Contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.
|10. DRUG INTERACTIONS – Clindamycin|
|Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.
Antagonism has been demonstrated between clindamycin and erythromycin in vitro. Because of possible clinical significance, these two drugs should not be administered concurrently.
|11. EXCRETION – Clindamycin|
|Approximately 10% of the bioactivity is excreted in the urine and 3.6% in the feces; the remainder is excreted as bioinactive metabolites.